Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).

被引：0
|
作者：
Rodriguez, Laura Medina
Guerra, Juan Antonio
Malon, Diego
Laura, Rodriguez
Colomer, Ramon
Quintela-Fandino, Miguel
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS615
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Phase II trial of letrozole in combination with bevacizumab in patients with hormone receptor-positive metastatic breast cancer: Correlation of response with circulating endothelial (CEC) and epithelial cells (CTC)
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 163 - 164
  • [32] Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
    Zhe-Yu Hu
    Min Yan
    Huihua Xiong
    Li Ran
    Jincai Zhong
    Ting Luo
    Tao Sun
    Ning Xie
    Liping Liu
    Xiaohong Yang
    Huawu Xiao
    Jing Li
    Binliang Liu
    Quchang Ouyang
    BMC Medicine, 21
  • [33] Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
    Hu, Zhe-Yu
    Yan, Min
    Xiong, Huihua
    Ran, Li
    Zhong, Jincai
    Luo, Ting
    Sun, Tao
    Xie, Ning
    Liu, Liping
    Yang, Xiaohong
    Xiao, Huawu
    Li, Jing
    Liu, Binliang
    Ouyang, Quchang
    BMC MEDICINE, 2023, 21 (01)
  • [34] Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial
    O'Shaughnessy, J.
    Yardley, D. A.
    Burris, H. A.
    De Boer, R.
    Amadori, D.
    McIntyre, K.
    Ejlertsen, B.
    Gnant, M.
    Jonat, W.
    Pritchard, K. I.
    Dowsett, M.
    Hart, L.
    Poggio, S.
    Valagussa, P.
    Salomon, H.
    Wamil, B.
    Smith, I.
    CANCER RESEARCH, 2016, 76
  • [35] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial.
    Lundkvist, J.
    Paulsson, T.
    Borgstrom, F.
    Kasteng, F.
    Sobocki, P.
    Lidgren, M.
    Henriksson, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
  • [36] A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
    Xu, Binghe
    Zhang, Qingyuan
    Hu, Xichun
    Li, Qing
    Sun, Tao
    Li, Wei
    Ouyang, Quchang
    Wang, Jingfen
    Tong, Zhongsheng
    Yan, Min
    Li, Huiping
    Zeng, Xiaohua
    Shan, Changping
    Wang, Xian
    Yan, Xi
    Zhang, Jian
    Zhang, Yue
    Wang, Jiani
    Zhang, Liang
    Lin, Ying
    Feng, Jifeng
    Chen, Qianjun
    Huang, Jian
    Lu, Yongkui
    Li, Hongsheng
    Wu, Jinsheng
    Cheng, Jing
    Hao, Yanrong
    Geng, Cuizhi
    Lu, Min
    Li, Yanping
    Chen, Xi
    Song, Lihua
    Wu, Xueying
    Hu, Changlu
    Wu, Xinhong
    Wang, Xiaojia
    Pan, Yueyin
    Cui, Yuehong
    Yu, Guohua
    Sun, Sanyuan
    CANCER RESEARCH, 2022, 82 (04)
  • [37] Phase II trial of palbociclib plus endocrine therapy followed by combination of pembrolizumab, palbociclib and endocrine therapy in patients with hormone receptor positive metastatic breast cancer
    Yuan, Yuan
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Stewart, Daphne
    Waisman, James
    Yap, Kelly
    Mortimer, Joanne
    Tank, Niki
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
    Perrone, Francesco
    De Laurentiis, Michelino
    De Placido, Sabino
    Orditura, Michele
    Cinieri, Saverio
    Riccardi, Ferdinando
    Ribecco, Angela Stefania
    Putzu, Carlo
    Del Mastro, Lucia
    Rossi, Emanuela
    Tinessa, Vincenza
    Mosconi, Anna Maria
    Nuzzo, Francesco
    Di Rella, Francesca
    Gravina, Adriano
    Iodice, Giovanni
    Landi, Gabriella
    Pacilio, Carmen
    Forestieri, Valeria
    Lauria, Rossella
    Fabbri, Agnese
    Ibrahim, Toni
    De Maio, Ermelinda
    Barni, Sandro
    Gori, Stefania
    Simeon, Vittorio
    Arenare, Laura
    Daniele, Gennaro
    Piccirillo, Maria Carmela
    Normanno, Nicola
    de Matteis, Andrea
    Gallo, Ciro
    EUROPEAN JOURNAL OF CANCER, 2019, 118 : 178 - 186
  • [39] Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer (MBC) - Results of the eLEcTRA Trial
    Huober, J.
    Fasching, P.
    Paepke, S.
    Kubista, E.
    Barsoum, M.
    Wallwiener, D.
    Harbeck, N.
    CANCER RESEARCH, 2009, 69 (24) : 737S - 738S
  • [40] Adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen for hormone receptor-positive breast cancer in women younger than 35 (ASPAIT): A multicenter randomized clinical trial
    Shan, Zhen
    Shao, Nan
    Yuan, Zhongyu
    Chen, Qianjun
    Zhang, Anqin
    Wang, Kun
    Zhang, Ailing
    Cai, Li
    Song, Yuhua
    Yao, Herui
    Ma, Hongmin
    Huang, Heng
    Li, Jianwen
    Zhang, Yuanqi
    Zhang, Lehong
    Zhong, Jincai
    Liu, Hui
    Wu, Zhiyong
    Zhao, Li
    Ling, Feihai
    Yang, Weixiong
    Zhuo, Rui
    Song, Xiangyang
    Lin, Ying
    CANCER RESEARCH, 2020, 80 (04)
12345